Ruth Board

3.9k total citations
57 papers, 1.9k citations indexed

About

Ruth Board is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ruth Board has authored 57 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 21 papers in Molecular Biology and 13 papers in Cancer Research. Recurrent topics in Ruth Board's work include Cancer Genomics and Diagnostics (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Melanoma and MAPK Pathways (10 papers). Ruth Board is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Melanoma and MAPK Pathways (10 papers). Ruth Board collaborates with scholars based in United Kingdom, Netherlands and France. Ruth Board's co-authors include Caroline Dive, Andrew Hughes, Malcolm Ranson, Gordon C. Jayson, Fiona Blackhall, Alastair Greystoke, Juan W. Valle, Matthew Krebs, Martyn Porter and Tim Board and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Radiology.

In The Last Decade

Ruth Board

52 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruth Board United Kingdom 23 1.0k 732 656 441 214 57 1.9k
Chunyi Hao China 24 871 0.9× 724 1.0× 330 0.5× 493 1.1× 376 1.8× 135 2.1k
Marine Gilabert France 22 910 0.9× 395 0.5× 399 0.6× 422 1.0× 276 1.3× 73 1.8k
Francesco Pantano Italy 25 993 1.0× 861 1.2× 577 0.9× 549 1.2× 236 1.1× 109 2.1k
Bonnie L. Kemp United States 24 765 0.8× 994 1.4× 558 0.9× 709 1.6× 365 1.7× 38 2.5k
Ricardo Costa United States 22 1.1k 1.1× 848 1.2× 540 0.8× 601 1.4× 204 1.0× 82 2.2k
Akihiko Shimomura Japan 22 1.1k 1.1× 751 1.0× 537 0.8× 536 1.2× 137 0.6× 132 2.0k
Nadia Dandachi Austria 23 799 0.8× 565 0.8× 508 0.8× 215 0.5× 130 0.6× 57 1.5k
Waldemar Wilczak Germany 30 842 0.8× 1.1k 1.5× 599 0.9× 826 1.9× 344 1.6× 93 2.3k
Sebastian Aulmann Germany 31 910 0.9× 1.0k 1.4× 667 1.0× 795 1.8× 324 1.5× 74 2.4k
Lydia Nakopoulou Greece 27 863 0.8× 1.0k 1.4× 684 1.0× 400 0.9× 330 1.5× 79 2.3k

Countries citing papers authored by Ruth Board

Since Specialization
Citations

This map shows the geographic impact of Ruth Board's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Board with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Board more than expected).

Fields of papers citing papers by Ruth Board

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Board. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Board. The network helps show where Ruth Board may publish in the future.

Co-authorship network of co-authors of Ruth Board

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Board. A scholar is included among the top collaborators of Ruth Board based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Board. Ruth Board is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dayimu, Alimu, Satish Kumar, David Burke, et al.. (2023). Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma. European Journal of Cancer. 194. 113344–113344. 1 indexed citations
3.
4.
Bolte, Laura A., Karla A. Lee, Johannes R. Björk, et al.. (2023). Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. JAMA Oncology. 9(5). 705–705. 51 indexed citations
5.
6.
Dalle, Stéphane, Laurent Mortier, Pippa Corrie, et al.. (2021). Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer. 21(1). 642–642. 12 indexed citations
7.
Goode, E., Danielle Crawley, Charlotte Moss, et al.. (2020). 243P UK experience of the management of pregnancy associated breast cancer: A national retrospective review of practice. Annals of Oncology. 31. S337–S337.
8.
Smith, Henry, Jessica Glen, Howard Peach, et al.. (2020). Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma. European Journal of Cancer. 135. 113–120. 20 indexed citations
9.
Board, Ruth, Martin Cook, Pippa Corrie, et al.. (2019). Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. Journal of Plastic Reconstructive & Aesthetic Surgery. 73(1). 36–42. 24 indexed citations
10.
Pickwell‐Smith, Benjamin, et al.. (2018). Managing side effects of cancer immunotherapy for the acute physician. British Journal of Hospital Medicine. 79(7). 372–377. 6 indexed citations
11.
Butler, Holly J., Ruth Board, Paul M. Brennan, et al.. (2018). Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open. 8(5). e017593–e017593. 39 indexed citations
12.
Board, Ruth, et al.. (2013). The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. Cancer Treatment Reviews. 39(8). 833–838. 19 indexed citations
13.
Board, Ruth, Andrew Wardley, J. Michael Dixon, et al.. (2010). Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment. 120(2). 461–467. 165 indexed citations
14.
Hawkins, Robert D., et al.. (2010). Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases. Urologia Internationalis. 86(2). 245–248. 6 indexed citations
15.
Board, Ruth, Gillian Ellison, Emma Donald, et al.. (2010). Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. PubMed. 4(1-4). 11–21. 36 indexed citations
16.
Board, Ruth, Gillian Ellison, Maria Orr, et al.. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. British Journal of Cancer. 101(10). 1724–1730. 78 indexed citations
17.
Hou, Jianmei, Alastair Greystoke, Lee Lancashire, et al.. (2009). Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal Of Pathology. 175(2). 808–816. 189 indexed citations
18.
Board, Ruth, Anjoeka Pronk, W. David J. Ryder, et al.. (2006). Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. International Journal of Gynecological Cancer. 16(S1). 18–24. 10 indexed citations
19.
Board, Ruth, Nick Thatcher, & Paul Lorigan. (2006). Novel Therapies for the Treatment of Small-Cell Lung Cancer. Drugs. 66(15). 1919–1931. 11 indexed citations
20.
Board, Ruth & Gordon C. Jayson. (2005). Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resistance Updates. 8(1-2). 75–83. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunyi Hao Breakdown of academic impact, for papers by Marine Gilabert Breakdown of academic impact, for papers by Francesco Pantano Breakdown of academic impact, for papers by Bonnie L. Kemp Breakdown of academic impact, for papers by Ricardo Costa Breakdown of academic impact, for papers by Akihiko Shimomura Breakdown of academic impact, for papers by Nadia Dandachi Breakdown of academic impact, for papers by Waldemar Wilczak Breakdown of academic impact, for papers by Sebastian Aulmann Breakdown of academic impact, for papers by Lydia Nakopoulou
Rankless by CCL
2026